![](/img/cover-not-exists.png)
PD6-3-5: Pharmacoeconomic analysis shows that erlotinib is cost-saving versus docetaxel, and cost-effective versus best supportive care (BSC) in NSCLC
Pompen, Marjolein, Novak, Annoesjka, Gok, Murat, Gyldmark, Marlene, Postmus, Pieter, Afram, CharlesVolume:
2
Language:
english
Journal:
Journal of Thoracic Oncology
DOI:
10.1097/01.JTO.0000283343.74967.96
Date:
August, 2007
File:
PDF, 164 KB
english, 2007